Year-end Sale % OFF 
Abstract
Objective: To evaluate the diagnostic possibilities of transabdominal ultrasonography for various localizations of gastric carcinoma (GC). Materials and Methods: The study included 101 patient with GC, the stage T1 in 5, the stage of T2 – in 12, the stage of T3 – in 39 and the stage of T4 – in 45 cases respectively. The stomach tumor in 37 (36.6%) cases was localized mainly in the antrum, 35 (34.6%) – in the body, 12 (11.9%) in the cardia and fundus, in 13 (12.9%) cases it had a total, in 4 (4.0%) - subtotal character. Ulcerating infiltrating forms (UIF) of GC was diagnosed in 71 cases, diffuse infiltrating forms (DIF) in 23 cases. All patients underwent preoperative X-ray, virtual gastroscopy techniques, multidetector computed tomography and transabdominal ultrasonography (USG). Results: The intestinal histological form of GC was detected in 7 cases – with USG in 6 cases. The UIF of GC with the help of USG was diagnosed in 69 (97,2%) cases, DIF – in 23 (100%) cases of T2-T4 stages. The results of USG and CT was coincided in all cases of T3 and in 92,7% of T4 stages of GC. Conclusions: The combined use of ultrasonography and gastroscopy will increase the detection of early intestinal type of GC. USG is the best, cheap, independent method for diagnosing a diffusely infiltrative form of GC, especially of the antrum. At stage T3, he is not inferior to CT in assessing the localization and prevalence of GC, and at stage T4, the difference between them is negligible.
Highlights
Gastric carcinoma (GC) is the fourth most common cancer worldwide and the second most common cause of cancer-related death
Though a marked reduction has been observed in the incidence of gastric carcinoma in North America and Western Europe in the last 50 years, 5-year survival rates are less than 20%, as most patients present late and are unsuitable for curative, radical surgery
The most commonly used staging system for GC was developed by the American Joint Committee on Cancer (AJCC) [1, 2]
Summary
Gastric carcinoma (GC) is the fourth most common cancer worldwide and the second most common cause of cancer-related death. Though a marked reduction has been observed in the incidence of gastric carcinoma in North America and Western Europe in the last 50 years, 5-year survival rates are less than 20%, as most patients present late and are unsuitable for curative, radical surgery. That is an aggressive carcinoma with 5-year survival rates ranging from 3% in the case of stage IV tumors to 85–90% in the case of stage I tumors. Gastric adenocarcinoma has shown a marked decline in the last decades. There seems to be an increase in carcinomas localized to the cardia, especially in younger women and older men [3]. Other studies have failed to demonstrate such an increase [4, 5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Journal of Clinical and Experimental Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
